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Andreas H Diacon, Michael Hoelscher, on behalf of the Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA)
Summary
Background An accurate biomarker is urgently needed to monitor the response to treatment in patients with 
pulmonary tuberculosis. The Xpert MTB/RIF assay is a commercially available real-time PCR that can be used to 
detect Mycobacterium-tuberculosis-speciﬁ c DNA sequences in sputum samples. We therefore evaluated this assay with 
serial sputum samples obtained over 26 weeks from patients undergoing treatment for tuberculosis.
Methods We analysed sputum samples from 221 patients with smear-positive tuberculosis enrolled at two sites (Cape 
Town, South Africa, and Mbeya, Tanzania) of a multicentre randomised clinical trial REMoxTB of antituberculosis 
treatment on a weekly basis (weeks 0 to 8), then at weeks 12, 17, 22, and 26 after treatment initiation. The Xpert 
MTB/RIF results over time were compared with the results of standard smear microscopy and culture methods.
Findings We obtained and analysed 2741 sputum samples from 221 patients. The reduction in positivity rates with 
Xpert MTB/RIF were slower than those with the standard methods. At week 8, positive results were obtained for 
62 (29%) of 212 sputum samples with smear microscopy, 46 (26%) of 175 with solid culture (Löwenstein-Jensen 
medium), 77 (42%) of 183 with liquid culture (Bactec MGIT960 system), and 174 (84%) of 207 with Xpert MTB/RIF; 
at 26 weeks, positive results were obtained for ten (5%) of 199, four (3%) of 157, seven (4%) of 169, and 22 (27%) of 83 
sputum samples, respectively. The reduction in detection of quantitative M tuberculosis DNA with Xpert MTB/RIF 
correlated with smear grades (ˮ=–0·74; p<0·0001), solid culture grades (ˮ=–0·73; p<0·0001), and time to liquid 
culture positivity (ˮ=0·73; p<0·0001). Compared with the combined binary smear and culture results as a reference 
standard, the Xpert MTB/RIF assay had high sensitivity (97·0%, 95% CI 95·8–97·9), but poor speciﬁ city (48·6%, 
45·0–52·2).
Interpretation The poor speciﬁ city precludes the use of the Xpert MTB/RIF assay as a biomarker for monitoring 
tuberculosis treatment, and should not replace standard smear microscopy and culture.
Funding Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation, UK Medical Research Council, 
German Ministry of Science and Technology.
Introduction
Substantial progress has been made in global tuberculosis 
control but these gains are threatened by the global spread 
of drug-resistant tuberculosis.1 The urgency of this 
situation calls for better treatment markers that can be 
used to detect insuﬃ  cient treatment—the main cause of 
the emergence of resistance—early and easily. Additionally, 
the clinical development of the emerging new portfolio of 
tuberculosis drugs2 could be accelerated if phase 2 and 3 
trials could be greatly shortened and reliable surrogate 
markers used for the measurement of treatment success.3
Current biomarkers that have been used as predictors 
of non-relapsing cure are sputum-smear microscopy and 
sputum-culture conversion,4 both of which have 
shortcomings as markers for the measurement of 
treatment response. Sputum-smear microscopy is 
insensitive, operator dependent, and has been shown to 
be a poor predictor of treatment outcome.5 It cannot be 
used to diﬀ erentiate between Mycobacterium tuberculosis 
and non-tuberculosis mycobacteria reliably6 and between 
live and dead bacilli. Sputum culture takes a long time, is 
prone to contamination, is expensive, and is rarely 
available in high-burden settings. In the absence of an 
ideal marker to measure treatment success in individuals, 
WHO currently recommends smear microscopy at 
month 2 to identify individuals at risk of poor treatment 
outcome. Also, in recent clinical studies of bedaquiline 
(TMC207)7,8 and delamanid (OPC-67683),9 both 
biomarkers have been used to predict the therapeutic 
value of early drug regimens. Sputum-culture conversion 
at 8 weeks has some predictive value for the measurement 
of the sterilising activity of a novel regimen.10 Potentially 
more promising, but not yet suﬃ  ciently validated, is the 
time to culture positivity measured with semiautomated 
liquid culture.11–13
Although several other M tuberculosis and human 
biomarkers have been studied over the past decade,14,15 
including M tuberculosis DNA-based and RNA-based 
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assays,16–18 no new speciﬁ c and accurate biomarkers of 
disease activity and relapse have yet been validated. 
Therefore, an urgent need exists for biomarkers that can 
be used to accurately measure bacillary clearance and 
identify individuals receiving insuﬃ  cient treatment with 
high risk of tuberculosis recurrence. Furthermore, for 
innovative trial designs in which the aim is to reduce the 
size and duration of clinical trials, the use of faster 
surrogate endpoints for treatment eﬃ  cacy, disease 
activity, cure, and relapse will be indispensable.3 
WHO approved the Xpert MTB/RIF assay (Cepheid, 
Sunnyvale, CA, USA) for sputum-based rapid diagnosis 
of pulmonary tuberculosis and multidrug-resistant 
(MDR) tuberculosis. The assay can be used to accurately 
measure the M tuberculosis load beyond the detection 
limit of 131 organisms per mL in an in-vitro suspension.19,20 
The Xpert MTB/RIF assay in patients with suspected 
tuberculosis and newly diagnosed cases of tuberculosis 
has been evaluated in several studies.21–24 The results of 
these studies suggested that the Xpert MTB/RIF assay is 
better than sputum-smear microscopy; its quantitative 
readouts correlate well with results of conventional solid 
and liquid cultures.21–24 Speciﬁ cally, for the detection of 
tuberculosis and MDR-tuberculosis in HIV-positive 
individuals, a cost beneﬁ t was noted compared with 
conventional smear microscopy.25,26 In this respect, 
detection of M tuberculosis DNA in serial sputum samples 
over time with the Xpert MTB/RIF assay could have the 
potential to replace conventional microbiological tests for 
monitoring response to tuberculosis treatment regimens. 
We evaluated the Xpert MTB/RIF assay in serial sputum 
samples obtained over 26 weeks of tuberculosis treatment 
from patients enrolled in the multicentre randomised 
clinical trial REMoxTB (ClinicalTrials.gov, NCT00864383). 
Methods
Patients and study design
In this substudy, we obtained sputum samples from a 
subset of 221 participants enrolled in the multicentre, 
randomised clinical drug trial REMoxTB at two of the 
47 clinical trial sites in Cape Town, South Africa, and 
Mbeya, Tanzania, between January, 2008, and April, 2010. 
In the REMoxTB trial, 1931 patients with previously 
untreated, drug-sensitive, smear-positive, pulmonary 
tuberculosis were enrolled between January, 2008, and 
January, 2012. HIV-positive patients with a CD4-cell count 
of fewer than 2·5 × 10⁸ per L or those already on 
antiretroviral treatment were excluded to avoid 
concomitant antiretroviral treatment, according to current 
practice at the time the protocol was prepared. All 
participants were treated for tuberculosis either with one 
of two treatment-shortening regimens of 4 months, in 
which moxiﬂ oxacin was substituted for either isoniazid or 
ethambutol or with the standard 6 month regimen 
(2 months of isoniazid, rifampicin, ethambutol, and 
pyrazinamide followed by 4 months of isoniazid and 
rifampicin). Every patient was followed up for a total of 
18 months. To avoid interference with the endpoints of the 
main treatment trial, the sample analysis with Xpert 
MTB/RIF was restricted until week 26 and all investigators 
were still masked to the treatment allocations. The results 
of the main study will become available in 2014.
Ethical and regulatory approval, granted by all local and 
national ethics committees and regulatory authorities, 
included the permission to undertake studies to improve 
treatment and diagnosis of tuberculosis. 
Sputum samples
All participants were invited for regular visits to the study 
clinics and asked to provide one early morning sputum 
sample, which was spontaneously expectorated at home 
or at the clinics before treatment (week 0) and then 
weekly until week 8, followed by monthly sputum sample 
collection (weeks 12, 17, and 22) until week 26 after 
treatment initiation. Sputum specimens were processed 
by two study laboratories (Department of Biomedical 
Sciences, University of Stellenbosch, and the tuberculosis 
laboratory at the National Institute for Medical 
Research-Mbeya Medical Research Centre) in accordance 
with the standardised REMoxTB laboratory manual at 
both laboratories. Brieﬂ y, a maximum of 10 mL of sample 
was homogenised and decontaminated with the 
N-acetyl-L-cysteine-sodium hydroxide procedure.27 After 
centrifugation for 15 min at 4°C and 3000×g, the resulting 
pellet was stored at 4°C for further analyses. 
30 μL of the concentrated sputum pellet was used for 
Ziehl-Neelsen staining followed by smear microscopy; 
1·5 mL phosphate-buﬀ ered saline (pH 6·8; Becton 
Dickinson, Sparks, MD, USA) was added and the pellet 
was resuspended. 500 μL of the suspension was used for 
evaluation in liquid culture with the Bactec MGIT960 
system (MGIT; Becton Dickinson) and 150 μL in solid 
culture on Löwenstein-Jensen medium (Becton 
Dickinson) with standard protocols. 
The remaining sputum pellet was mixed with 2 mL of 
the phosphate-buﬀ ered saline and vortexed. 1 mL was 
processed for evaluation in the Xpert MTB/RIF assay 
according to the manufacturer’s instructions by use of 
the GeneXpert Dx software (version 2.1 and 4.0) for 
automation of all PCR processing, reaction, and detection 
steps. The signals for ﬂ uorescence were recorded, 
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Both sites (n=221) Mbeya (n=90) Cape Town (n=131) p value*
Age (years) 30 (23–40) 30 (25–39) 30 (23–41) 0·43
Sex, male 144 (65%) 57 (63%) 87 (66%) 0·64
HIV-positive status 20 (9%) 16 (18%) 4 (3%) <0·0001
CD4-cell count×108 per L in 
participants who are 
HIV positive
3·62 (2·91–4·52) 3·59 (2·91–4·96) 3·92 (3·10–4·31) 0·56
Data are number (%) or median (IQR), unless otherwise indicated. *For diﬀ erence between sites, from Wilcoxon 
rank-sum test (binary variables) or two-sample test of proportions (continuous variables).
Table 1: Demographic and clinical characteristics of study participants
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analysed, and reported as semiquantitative readouts 
based on the minimal cycle threshold (CTmin), which is 
deﬁ ned as one of ﬁ ve probes speciﬁ c for M tuberculosis 
complex becoming positive for detection.2 
Statistical analysis
A negative result for smear microscopy was reported if no 
acid-fast bacilli were detected in at least 100 observation 
ﬁ elds. Cultures in MGIT and on Löwenstein-Jensen media 
were judged to have a negative result if no mycobacterial 
growth was seen until 6 weeks and 8 weeks after 
incubation, respectively. A tuberculosis negative result for 
the Xpert MTB/RIF assay was generated automatically 
following an interpretative algorithm with the GeneXpert 
Dx software. Apart from calculating binary (positive, 
negative) variables for all test outcomes, results were 
processed to analyse them quantitatively: the intensity 
grades for smear (0, 1+, 2+, 3+, 4+)28 and Löwenstein-Jensen 
(negative, <20 colonies, 1+, 2+, 3+) were coded into ﬁ ve 
categories from 0 (negative) to 4. Time to positivity of 
MGIT and CTmin of the Xpert MTB/RIF assay were used as 
quantitative outcomes and both were coded as 50 days and 
50 cycles, respectively, if negative. Diagnostic test 
performance (sensitivity, speciﬁ city, negative predictive 
value, positive predictive value) and Spearman rank 
correlations were calculated with standard formulae. In 
the absence of a perfect and accurate marker for 
tuberculosis disease activity, treatment response, or 
treatment outcome, either the combined result for smear 
microscopy, Löwenstein-Jensen culture, and MGIT 
culture, or each individual test was used as reference 
standard for the calculation of accuracy of the Xpert 
MTB/RIF assay. Diﬀ erences between groups were tested 
for signiﬁ cance with the two-sample proportion Z test for 
binary variables and the non-parametric Wilcoxon rank 
sum test for continuous variables because none of the 
results conformed to a normal distribution. Longitudinal 
CTmin values over time were analysed by use of the non-linear 
least-squares estimation and non-linear mixed-eﬀ ects 
models to better account for between-patient variability. 
The same biexponential model was used previously to ﬁ t 
to these type of data.18,29 Stata software (version 12.1) was 
used for all statistical analyses with the exception of the 
non-linear mixed-eﬀ ects models, which were ﬁ t using the 
nlme package in R (version 2.9.0).
Role of the funding source
The study was a collaboration between the Global TB 
Alliance and the Pan African Consortium for the 
Evaluation of Anti-tuberculosis Antibiotics (PanACEA). 
This study was undertaken with permission from the 
REMox trial sponsor, but the study design, data collection, 
analysis, and interpretation, and writing of the report 
were done independently. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
2741 sputum specimens were obtained and analysed from 
221 patients (131 in Cape Town, 90 in Mbeya) from 
weeks 0–26 after initiation of antituberculosis treatment. 
Table 1 shows the demographic characteristics of the 
patients.
Figure 1 shows the qualitative data and table 2 the 
quantitative data for all tests at baseline and follow-up 
visits. Valid smear results were available for 2732 samples 
and valid Xpert MTB/RIF assay results for 2000 samples. 
After exclusion of acid-fast-bacillus-negative, but 
contaminated, cultures and those with no speciation 
result, 2324 and 2383 results for Löwenstein-Jensen and 
MGIT cultures, respectively, were included in the 
qualitative analysis (ﬁ gure 1). There were 262 (11%) of 
2383 acid-fast-bacillus-positive MGIT cultures showing 
contamination; these were excluded from the calculation 
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Figure 1: Qualitative data for all tests at baseline and follow-up visits
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of the mean time to positivity (table 2). Because only 
patients with smear-positive tuberculosis were included 
in the trial after screening, 92% and 98% of baseline 
values for smear microscopy and all other diagnostic 
tests, respectively, were positive for M tuberculosis 
(ﬁ gure 1; table 2). Similarly, at week 0, quantitative 
measurements were lowest for Xpert MTB/RIF CTmin and 
MGIT time to positivity, and highest for smear and 
Löwenstein-Jensen grade (ﬁ gure 1; table 2). The sputum 
load of M tuberculosis measured with smear and culture 
tests fell rapidly and consistently after induction of 
treatment (ﬁ gure 1; table 2). A delayed, less rapid, and 
almost linear fall in the mycobacterial load was noted 
with the Xpert MTB/RIF assay (ﬁ gure 1). For instance, 
84% of the sputum samples were still positive with the 
Xpert MTB/RIF assay at 8 weeks after treatment initiation 
whereas 29% were smear positive (table 2). Furthermore, 
at the end of the observation period (week 26), 27% of the 
samples were positive with the Xpert MTB/RIF assay but 
only 3% and 4% with the Löwenstein-Jensen and MGIT 
cultures, respectively (table 2).
To further elaborate the ﬁ ndings, we used three 
diﬀ erent statistical models to calculate the increase in 
CTmin with the Xpert MTB/RIF assay (ﬁ gure 2). In model 1, 
all negative results from the analysis were excluded. In 
model 2, a patient’s ﬁ rst negative result was imputed with 
a CTmin of 50 and the subsequent negative results were 
excluded. In model 3, all negative results were imputed 
with a CTmin of 50. The raw means (excluding negative 
results) with 95% CIs and raw medians were plotted by 
visit week. Figure 2 shows the ﬁ tted line for each model 
with the raw means and medians for CTmin. During the 
ﬁ rst 7 weeks, when there were few negative results with 
the Xpert MTB/RIF assay, the lines for the mean and 
median values were close, indicating that the distribution 
of CTmin was symmetrical. Assuming that the underlying 
distribution of CTmin remains symmetrical throughout the 
observation period, the median is judged to be a better 
summary measure than the mean for calculations with 
the symmetrically distributed data for CTmin because no 
assumptions are needed for values greater than the limit 
of detection, as is the case for models 1–3. Therefore, 
although, the increase in mean CTmin suggested a shallower 
slope after week 8, the median continued to increase 
almost linearly until week 17. The lines for all models had 
linear slopes with slightly ﬂ attened curves after week 12, 
depending on the inclusion of the negative results as 
determined by the model. Numerical values for the 
Week 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 12 Week 17 Week 22 Week 26
Smear 
microscopy, 
positive 
results
204/221
(92%)
198/218
(91%)
173/217
(80%)
150/215 
(70%)
127/212 
(60%)
105/207 
(51%)
83/206 
(40%)
74/210 
(35%)
62/212 
(29%)
31/210 
(15%)
13/202 
(6%)
3/203
(1%)
10/199 
(5%)
Smear 
microscopy, 
grade 
3·3
(3·1–3·4)
2·9
(2·7–3·1)
2·3
(2·1–2·5)
1·8 
(1·6–2·0)
1·5 
(1·3–1·7)
1·2 
(1·0–1·3)
0·8 
(0·6–1·0)
0·7 
(0·5–0·8)
0·5 
(0·4–0·6)
0·3 
(0·2–0·4)
0·1 
(0·1–0·2)
0·0 
(0·0–0·1)
0·1 
(0·0–0·2)
Löwenstein-
Jensen 
medium, 
positive 
results
188/191
(98%)
195/202
(97%)
176/189
(93%)
172/194 
(89%)
145/178 
(81%)
122/179 
(68%)
100/184 
(54%)
65/176 
(37%)
46/175 
(26%)
14/179 
(8%)
0/168
(0%)
3/152
(2%)
4/157
(3%)
Löwenstein-
Jensen 
medium, 
grade
3·6
(3·5–3·7)
3·0
(2·8–3·1)
2·5
(2·3–2·7)
2·0 
(1·8–2·2)
1·7 
(1·5–1·8)
1·2 
(1·1–1·4)
0·9 
(0·8–1·1)
0·6 
(0·4–0·7)
0·5 
(0·3–0·6)
0·2 
(0·1–0·3)
0·0 
(0·0–0·0)
0·1 
(0·0–0·1)
0·1
(0·0–0·2)
Bactec 
MGIT960 
system, 
positive 
results
215/219
(98%)
205/210
(98%)
186/195
(95%)
173/187 
(93%)
154/184 
(84%)
128/170 
(75%)
124/174 
(71%)
95/173 
(55%)
77/183 
(42%)
27/181 
(15%)
1/168 
(<1%)
3/170
(2%)
7/169
(4%)
Bactec 
MGIT960 
system, time 
to positivity 
(days)
6·0
(5·0–7·0)
10·2
(9·1–11·2)
13·5
(12·0–15·0)
16·0 
(14·1–17·8)
21·3 
(18·9–23·6)
24·9 
(22·2–27·6)
29·2 
(26·4–32·0)
35·0 
(32·3–37·7)
39·0 
(36·5–41·4)
46·0 
(44·1–47·8)
49·7 
(49·2–50·3)
49·2 
(48·4–50·1)
48·5 
(47·3–49·7)
Xpert MTB/
RIF assay, 
positive 
results
215/219
(98%)
214/219
(98%)
85/87
(98%)
85/88 
(97%)
196/212 
(92%)
85/89 
(96%)
78/86 
(91%)
80/89 
(90%)
174/207 
(84%)
131/198 
(66%)
107/198 
(54%)
72/196 
(37%)
22/83
(27%)
Xpert MTB/
RIF assay, CTmin 
19·0
(18·1–19·8)
20·4
(19·6–21·3)
20·2
(19·0–21·4)
21·7 
(20·3–23·1)
25·1 
(23·9–26·3)
24·2 
(22·7–25·7)
26·1 
(24·3–28·0)
27·1 
(25·2–29·0)
29·2 
(27·9–30·6)
34·6 
(32·9–36·2)
38·4 
(36·9–40·0)
42·4 
(40·9–43·8)
44·2 
(42·1–46·4)
Binary data are n/N (%) and quantitative data are mean (95% CI).
Table 2: Quantitative data for all tests  at baseline and follow-up visits 
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medians at weeks 22 and 26 could not be calculated 
because more than 50% of patients had negative results 
in the Xpert MTB/RIF assay (ﬁ gure 2).1
To investigate the relation between CTmin and the 
quantitative readouts for the smear, Löwenstein-Jensen, 
and MGIT assays, the Spearman rank correlation 
coeﬃ  cient was calculated for each study timepoint. The 
magnitudes of the overall correlation coeﬃ  cients (ˮ) over 
the entire 26 weeks were almost identical for smear 
(–0·74; p<0·0001), Löwenstein-Jensen (–0·73; p<0·0001), 
and MGIT (0·73; p<0·0001). Correlations were variable at 
discrete timepoints. CTmin values correlated moderately 
10
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Weeks after treatment initiation
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Raw median
Model 1
Model 2
Model 3
Figure 2: Increase in CTmin during tuberculosis treatment ﬁ tted with three diﬀ erent statistical models 
Note break in y axis. The horizontal line is the positivity cutoﬀ  value. CTmin=minimal cycle threshold.
Number of 
comparisons
Sensitivity (true positives/false 
negatives; %, 95% CI)
Speciﬁ city (true negatives/false 
positives; %, 95% CI)
Positive predictive 
value (%, 95% CI)
Negative predictive 
value (%, 95% CI)
Week 0 219 214/3 (98·6, 96·0–99·7) 1/1 (50·0, 1·3–98·7) 99·5 (97·4–100·0) 25·0 (0·6–80·6)
Week 1 216 210/4 (98·1, 95·3–99·5) 1/1 (50·0, 1·3–98·7) 99·5 (97·4–100·0) 20·0 (0·5–71·6)
Week 2 85 83/1 (98·8, 93·5–100·0) 1/0 (100·0, 2·5–100·0) 100·0 (95·7–100·0) 50·0 (1·3–98·7)
Week 3 87 82/1 (98·8, 93·5–100·0) 2/2 (50·0, 6·8–93·2) 97·6 (91·7–99·7) 66·7 (9·4–99·2)
Week 4 206 178/3 (98·3, 95·2–99·7) 11/14 (44·0, 24·4–65·1) 92·7 (88·1–96·0) 78·6 (49·2–95·3)
Week 5 87 78/1 (98·7, 93·2–100·0) 3/5 (37·5, 8·5–75·5) 94·0 (86·5–98·0) 75·0 (19·4–99·4)
Week 6 86 65/2 (97·0, 89·6–99·6) 6/13 (31·6, 12·6–56·6) 83·3 (73·2–90·8) 75·0 (34·9–96·8)
Week 7 86 44/4 (91·7, 80·0–97·7) 5/33 (13·2, 4·4–28·1) 57·1 (45·4–68·4) 55·6 (21·2–86·3)
Week 8 200 101/6 (94·4, 88·2–97·9) 25/68 (26·9, 18·2–37·1) 59·8 (52·0–67·2) 80·6 (62·5–92·6)
Week 12 196 44/8 (84·6, 71·9–93·1) 57/87 (39·6, 31·5–48·1) 33·6 (25·6–42·4) 87·7 (77·2–94·5)
Week 17 191 12/1 (92·3, 64·0–99·8) 86/92 (48·3, 40·8–55·9) 11·5 (6·1–19·3) 98·9 (93·8–100·0)
Week 22 179 3/1 (75·0, 19·4–99·4) 115/60 (65·7, 58·2–72·7) 4·8 (1·0–13·3) 99·1 (95·3–100·0)
Week 26 80 3/0 (100·0, 29·2–100·0) 59/18 (76·6, 65·6–85·5) 14·3 (3·1–36·3) 100·0 (93·9–100·0)
Overall 1918 1117/35 (97·0, 95·8–97·9) 372/394 (48·6, 45·0–52·2) 73·9 (71·6–76·1) 91·4 (88·2–93·9)
Data for sensitivity, speciﬁ city, positive predictive value, and negative predictive value are calculated against the reference standard. Samples with a negative smear result and 
missing culture result (Löwenstein-Jensen medium and Bactec MGIT960 system) were excluded from the analysis, and samples with a positive smear result and missing 
culture result (Löwenstein-Jensen medium and Bactec MGIT960 system) were included in the analysis.  
Table 3: Diagnostic performance of Xpert MTB/RIF assay compared with the combined reference standard (smear microscopy, Löwenstein-Jensen 
medium, and Bactec MGIT960 system)
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with smear microscopy, Löwenstein-Jensen solid culture, 
and MGIT liquid culture in the ﬁ rst 8 weeks but showed 
poorer correlation thereafter.
We analysed the Xpert MTB/RIF assay for prediction 
of the binary smear and culture results at consecutive 
timepoints during treatment. Although the overall 
sensitivity of the assay was 97%, speciﬁ city was low 
compared with the reference standard, which combined 
smear microscopy, MGIT, and Löwenstein-Jensen 
results (table 3). At baseline and early follow-up visits, 
the putative poor speciﬁ city of Xpert MTB/RIF assay was 
misleading because it was caused by false-negative 
microbiological results with the reference methods and 
a very low number of patients. Of greater relevance was 
the low speciﬁ city at weeks 6–12, indicating a delayed 
Xpert MTB/RIF assay conversion compared with smear 
and culture methods (ﬁ gure 1; table 3). The diagnostic 
performance of the Xpert MTB/RIF assay versus smear 
or culture methods alone did not show substantially 
diﬀ erent values (table 4). Notably, compared with MGIT, 
the Xpert MTB/RIF assay sensitivity and negative 
predictive value for culture positivity were both 100% 
from week 17 onwards (table 4; appendix). 
We also investigated whether any change in CTmin over 
time or absolute CTmin could be used to predict a patient’s 
conversion to a negative smear or culture result during 
treatment and did not ﬁ nd it to be predictive (data not 
shown).
Discussion
The important ﬁ ndings of our study are that 
quantitative Xpert MTB/RIF assay readouts for sputum 
M tuberculosis DNA as a biomarker correlate well with 
M tuberculosis smear and culture results during 
antituberculosis treatment. Positivity rates for sputum 
M tuberculosis DNA detection with Xpert MTB/RIF 
assay decline more slowly than do those with 
conventional sputum smear microscopy, solid culture, 
and liquid culture and seemed to be linear throughout 
treatment. Compared with a combined reference 
standard of smear and culture methods, the Xpert 
MTB/RIF assay had high sensitivity (97%) but poor 
speciﬁ city (49%; table 3). To our knowledge, this study 
is the ﬁ rst evaluation of the capacity of the 
Xpert MTB/RIF assay as an early sputum biomarker of 
response for monitoring tuberculosis treatment, and 
Smear microscopy Löwenstein-Jensen medium Bactec MGIT 960 system
Sensitivity Speciﬁ city Positive 
predictive 
value
Negative 
predictive 
value
Sensitivity Speciﬁ city Positive 
predictive 
value
Negative 
predictive 
value
Sensitivity Speciﬁ city Positive 
predictive 
value
Negative 
predictive 
value
Week 0 98·5% 
(95·7–99·7)
5·9% 
(0·2–28·7)
92·6% 
(88·2–95·7)
25·0% 
(0·6–80·6)
98·4% 
(95·4–99·7)
33·3% 
(0·8–90·6)
98·9% 
(96·2–99·9)
25·0% 
(0·6–80·6)
98·6% 
(95·9–99·7)
25·0% 
(0·6–80·6)
98·6% 
(95·9–99·7)
25·0% 
(0·6–80·6)
Week 1 100·0% 
(98·1–100·0)
25·0% 
(8·7–49·1)
92·9% 
(88·6–96·0)
100·0% 
(47·8–100·0)
100·0% 
(98·1–100·0)
57·1% 
(18·4–90·1)
98·5% 
(95·6–99·7)
100·0% 
(39·8–100·0)
98·0% 
(95·0–99·5)
20·0% 
(0·5–71·6)
98·0% 
(95·0–99·5)
20·0% 
(0·5–71·6)
Week 2 98·5% 
(92·1–100·0)
5·3% 
(0·1–26·0)
78·8% 
(68·6–86·9)
50·0% 
(1·3–98·7)
98·7% 
(92·7–100·0)
33·3% 
(0·8–90·6)
97·3% 
(90·7–99·7)
50·0% 
(1·3–98·7)
98·7% 
(93·2–100·0)
25·0% 
(0·6–80·6)
96·3% 
(89·6–99·2)
50·0% 
(1·3–98·7)
Week 3 98·2% 
(90·5–100·0)
6·3% 
(0·8–20·8)
64·7% 
(53·6–74·8)
66·7% 
(9·4–99·2)
98·6% 
(92·4–100·0)
20·0% 
(2·5–55·6)
89·7% 
(80·8–95·5)
66·7% 
(9·4–99·2)
98·6% 
(92·6–100·0)
28·6% 
(3·7–71·0)
93·5% 
(85·5–97·9)
66·7% 
(9·4–99·2)
Week 4 99·2% 
(95·7–100·0)
18·1% 
(10·5–28·1)
64·8% 
(57·6–71·5)
93·8% 
(69·8–99·8)
98·6% 
(95·0–99·8)
30·3% 
(15·6–48·7)
85·9% 
(79·6–90·8)
83·3% 
(51·6–97·9)
98·7% 
(95·3–99·8)
30·0% 
(14·7–49·4)
87·7% 
(81·8–92·2)
81·8% 
(48·2–97·7)
Week 5 97·0% 
(84·2 –99·9)
5·4% 
(1·1–14·9)
37·7% 
(27·4–48·8)
75·0% 
(19·4–99·4)
98·3% 
(91·1–100·0)
12·5% 
(2·7–32·4)
73·8% 
(62·7–83·0)
75·0% 
(19·4–99·4)
98·3% 
(90·9–100·0)
17·7% 
(3·8–43·4)
80·6% 
(69·5–88·9)
75·0% 
(19·4–99·4)
Week 6 100·0% 
(85·2–100·0)
12·7% 
(5·7–23·5)
29·5% 
(19·7–40·9)
100·0% 
(63·1–100·0)
95·7% 
(85·5–99·5)
17·7% 
(6·8–34·5)
61·6% 
(49·5–72·8)
75·0% 
(34·9–96·8)
98·2% 
(90·5–100·0)
23·8% 
(8·2–47·2)
77·5% 
(66·0–86·5)
83·3% 
(35·9–99·6)
Week 7 95·8% 
(78·9 –99·9)
12·3% 
(5·5–22·8)
28·8% 
(19·2–40·0)
88·9% 
(51·8–99·7)
96·0% 
(79·7–99·9)
14·0% 
(5·8–26·7)
35·8% 
(24·5–48·5)
87·5% 
(47·4–99·7)
90·9% 
(78·3–97·5)
12·9% 
(3·6–29·8)
59·7% 
(47·0–71·5)
50·0% 
(15·7–84·3)
Week 8 98·4% 
(91·2–100·0)
21·4% 
(15·0–29·0)
34·5% 
(27·5–42·1)
96·9% 
(83·8–99·9)
95·6% 
(84·9–99·5)
16·8% 
(10·7–24·5)
29·3% 
(22·1–37·3)
91·3% 
(72·0–98·9)
94·7% 
(86·9–98·5)
22·6% 
(14·9–31·9)
47·3% 
(39·1–55·6)
85·2% 
(66·3–95·8)
Week 12 100·0% 
(88·1–100·0)
39·6% 
(32·2–47·4)
22·1% 
(15·4–30·2)
100·0% 
(94·6–100·0)
71·4% 
(41·9–91·6)
35·9% 
(28·4–44·0)
9·1% 
(4·5–16·1)
93·3% 
(83·8–98·2)
76·9% 
(56·4–91·0)
34·5% 
(26·9–42·7)
17·1% 
(10·8–25·2)
89·5% 
(78·5–96·0)
Week 17 91·7% 
(61·5–99·8)
48·9% 
(41·5–56·4)
10·5% 
(5·4–18·0)
98·9% 
(94·0–100·0)
·· ·· ·· ·· 100·0% 
(2·5–100·0)
45·1% 
(37·4–53·1)
1·1% 
(0·0–6·0)
100·0% 
(95·1–100·0)
Week 22 66·7% 
(9·4–99·2)
63·7% 
(56·5–70·5)
2·8% 
(0·3–9·7)
99·2% 
(95·6–100·0)
100·0% 
(29·2–100·0)
68·1% 
(59·8–75·6)
6·1% 
(1·3–16·9)
100·0% 
(96·3–100·0)
100·0% 
(29·2–100·0)
64·8% 
(56·9–72·1)
5·0% 
(1·0–13·9)
100·0% 
(96·6–100·0)
Week 26 100·0% 
(15·8–100·0)
75·3% 
(64·5–84·2)
9·1% 
(1·1–29·2)
100·0% 
(94·1–100·0)
100·0% 
(15·8–100·0)
77·1% 
(65·6–86·3)
11·1% 
(1·4–34·7)
100·0% 
(93·4–100·0)
100·0% 
(15·8–100·0)
76·8% 
(65·1–86·1)
11·1% 
(1·4–34·7)
100·0% 
(93·3–100·0)
Overall 98·7% 
(97·7–99·3)
36·8% 
(34·0–39·7)
53·7% 
(51·1–56·2)
97·4% 
(95·4–98·7)
98·0% 
(96·9–98·9)
40·1% 
(37·6–44·4)
63·5% 
(60·8–66·1)
95·2% 
(92·4–97·2)
97·3% 
(96·0–98·2)
43·5% 
(39·9–47·1)
68·9% 
(66·4–71·4)
92·5% 
(89·3–95·0)
Data are percentage (95% CI). Data for sensitivity, speciﬁ city, positive predictive value, and negative predictive value were calculated against individual reference standards
Table 4: Diagnostic performance of Xpert MTB/RIF assay compared with smear microscopy, Löwenstein-Jensen medium, and Bactec MGIT960 system 
See Online for appendix
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as a alternative for standard smear microscopy and 
culture (panel).
The Xpert MTB/RIF assay is assumed to be speciﬁ c; it 
only detects DNA from intact M tuberculosis bacilli and 
contamination from free DNA is thought to be removed 
by a washing step.20,30 The assay, however, does not 
diﬀ erentiate between viable, dormant,31 and non-viable 
intact M tuberculosis bacilli that are shed during eﬀ ective 
antituberculosis treatment. Furthermore, our ﬁ ndings—
high rates of positive results at the end of the 6 month 
treatment—suggest that even DNA fragments from 
lysed or damaged bacteria could have been detected by 
use of Xpert MTB/RIF. Detection of these bacteria would 
explain the lengthy and constant slope, indicating a 
linear decay of DNA and dead mycobacteria, and is in 
contrast to the biphasic curves reported for culture or 
RNA-based assays.12,18 By contrast with DNA, the 
presence and amount of M tuberculosis RNA, particularly 
mRNA, correlated well with culture positivity and viable 
colony counts, respectively,17,18,32 whereas DNA-based 
assays were also positive beyond culture conversion or 
even the end of successful treatment.16,33 The results of a 
recent study suggest that viable and non-viable 
M tuberculosis bacilli can be distinguished by use of 
propidiummonoazide, which enters damaged or 
non-viable mycobacteria, covalently binds to DNA after 
light-exposure, and prevents DNA ampliﬁ cation, such as 
in the Xpert MTB/RIF assay.34
The data show that detection of M tuberculosis DNA in 
sputum with the Xpert MTB/RIF assay in its current 
format cannot be used as a biomarker of disease activity 
and cannot replace conventional smear culture for the 
monitoring of patients undergoing treatment for 
tuberculosis. This is in agreement with the results of a 
recently reported study in which patients taking part in 
an early bactericidal activity trial were monitored by use 
of the Xpert MTB/RIF assay, and liquid and solid 
cultures; the Xpert MTB/RIF assay was the least suitable 
for the assessment of drug eﬃ  cacy.8 Hence, several 
aspects of the capacity of the assay for use in monitoring 
tuberculosis treatment require further study: whether 
the speciﬁ city of the Xpert MTB/RIF assay can be 
improved without aﬀ ecting sensitivity through the 
prevention of DNA ampliﬁ cation from dead bacteria; 
whether a positive or negative Xpert MTB/RIF assay 
result at the end of 6 months of tuberculosis treatment 
can be used to provide prognostic information about 
treatment failure and relapse; and the prognostic 
relevance of baseline quantitative values or the 
timepoint of conversion to negativity, which was shown 
for time to positivity with MGIT.13
This study has several advantages because it was nested 
in a clinical trial. A large number of samples (n=2741) 
were obtained and processed under standardised and 
highly monitored conditions, as shown by the robust and 
high-quality data generated at both study sites for the 
Xpert MTB/RIF assay, and smear and culture methods. 
The similarity of the data between diﬀ erent sites suggests 
that our ﬁ ndings could not be attributed to technical 
factors. The number of patients lost to follow-up was very 
low and the falling numbers of available results during 
follow-up are usually the result of patients being unable 
to produce sputum samples at the end of an eﬀ ective 
treatment. 
A limitation of this study is that the results of the 
Xpert MTB/RIF assay could not be linked with clinical 
outcomes such as cure and relapse. Since the REMoxTB 
trial is still in progress, information about the allocated 
tuberculosis treatment or the presence of drug 
resistance in relation to the patients’ responses to 
treatment was not available for data analysis in this 
study. However, because the Xpert MTB/RIF assay is 
widely available in many countries, clinicians might be 
starting to use this assay speculatively to monitor 
patients, as is commonly done with microscopy. 
Therefore, the results of our study are important 
because they show that the Xpert MTB/RIF assay is less 
responsive for the monitoring of tuberculosis treatment 
than is smear microscopy. 
Notably, however, the absence of an adequate reference 
standard, and the consecutive use of smear microscopy 
and culture as imperfect surrogates, might have distorted 
the results of the diagnostic performance of the 
Xpert MTB/RIF assay. The results are further limited by 
our study being undertaken in only two sites in Africa 
and in a population of patients who were not severely ill.
Our data indicate that the Xpert MTB/RIF assay in its 
current format is not suitable for the monitoring of 
Panel: Research in context
Systematic review
We did an online search of the PubMed database on Jan 31, 2011, to identify scientiﬁ c 
articles about the Xpert MTB/RIF assay published since Jan 1, 2010, using the terms “Xpert” 
or “GeneXpert” and “tuberculosis”. Only articles published in English were selected. Six 
articles were reviewed. The results of these studies showed the ability of this testing 
platform as a primary diagnostic method for detection of Mycobacterium tuberculosis mainly 
in expectorated sputum samples from patients with untreated tuberculosis.20–24 Although 
several studies have been planned, there are no reports of the use of the Xpert MTB/RIF 
assay to monitor tuberculosis treatment in the context of a clinical trial.
Interpretation
Previous research has shown that the Xpert MTB/RIF assay has a high speciﬁ city in the 
diagnosis of M tuberculosis with improved sensitivity compared with smear microscopy 
and culture. Thus, the available evidence shows that the Xpert MTB/RIF assay is useful as a 
primary diagnostic aid. In view of the need for improved biomarkers, researchers have 
speculated that the assay might be used to monitor treatment response and the samples 
available to us provided a unique opportunity to test this hypothesis. As a result, the Xpert 
MTB/RIF assay was compared with the standard method to assess its usefulness for 
treatment monitoring and its potential as a biomarker. We concluded that, in its current 
format, the Xpert MTB/RIF assay cannot be used to monitor antituberculosis treatment 
due to its slow decline in positivity compared with smear microscopy and culture. Future 
technological change that would eliminate the signal from dead bacilli could overcome 
this problem and provide a useful biomarker for use in resource-poor settings.
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tuberculosis treatment and, thus, cannot replace 
standard smear microscopy and culture. Therefore, 
technical improvements in the Xpert MTB/RIF assay 
that prevent the assay from detecting DNA from 
non-viable or even damaged bacteria will be needed 
before the test is suitable for monitoring patients in 
settings where it has already replaced smear microscopy 
as a diagnostic test. Larger studies with longer follow-up 
are needed to clarify the prognostic relevance of the 
Xpert MTB/RIF assay results for the prediction of 
treatment failure or relapse.
Contributors
All authors are part of PanACEA and the REMoxTB trial and contributed 
to the Article. TDM, SHG, AHD, and MH designed the study and 
protocols. Data were gathered by SOF, AR, AV, CDM, RD, CCB, and NH. 
SOF, AR, ES, PPJP, RDH, AHD, and MH undertook the management 
and the analyses of the data. SOF, AR, MH, AHD, SHG, TDM, MJB, 
and AZ wrote the ﬁ rst and ﬁ nal drafts. KS and AB contributed to the 
work through management and analysis of the data. All authors 
participated in writing the Article.
PanACEA
Medical Centre of the University of Munich, Munich, Germany 
(Sonja Henne, Anna Maria Mekota, Norbert Heinrich, Andrea Rachow, 
Anke Kohlenberg, Elmar Saathoﬀ , Michael Hoelscher); University of 
St Andrews, St Andrews, UK (Stephen Gillespie); Radboud University 
Nijmegen Medical Centre, Nijmegen, Netherlands 
(Georgette Plemper van Balen, Marloes Weijers, Rob Aarnoutse, 
Martin J Boeree); University College of London, London, UK 
(Anna Bateson, Timothy McHugh, Kasha Singh, Robert Hunt, 
Alimuddin Zumla); Medical Research Council Clinical Trials Unit, 
London, UK (Andrew Nunn, Patrick Phillips); University of Cape Town, 
Cape Town, South Africa (Rodney Dawson, Kim Narunsky); University 
of Stellenbosch, Cape Town, South Africa (Andreas Diacon, 
Jeannine du Bois, Amour Venter, Sven Friedrich); University of the 
Witswatersrand, Johannesburg, South Africa (Ian Sanne, Karla Mellet, 
Eefje de Jong); Aurum Institute, Johannesburg, South Africa 
(Gavin Churchyard, Salome Charalambous); University of Zambia, 
Lusaka, Zambia (Peter Mwaba); National Institute of Medical 
Research-Mbeya Medical Research Centre, Mbeya, Tanzania 
(Nyanda Elias, Chacha Mangu, Gabriel Rojas-Ponce, Bariki Mtafya, 
Leonard Maboko); Ifakara Health Institute-Bagamoyo Research and 
Training Centre, Bagamoyo, Tanzania (Klaus Reither, Levan Jugheli); 
Kilimanjaro Clinical Research Institute, Moshi, Tanzania (Noel Sam, 
Gibson Kibiki, Hadija Semvua, Stellah Mpagama); Medical Research 
Unit–Albert Schweitzer Hospital, Lambarene, Gabon (Abraham Alabi, 
Ayola Akim Adegnika); Kenya Medical Research Institute, Nairobi, 
Kenya (Evans Amukoye); Makerere University, Kampala, Uganda 
(Alphonse Okwera). 
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
PanACEA is funded by the European and Developing Countries Clinical 
Trials Partnership (grants numbers CT.2004.32011.001, IP.2007.32011.011, 
IP.2007.32011.012, IP.2007.32011.013), Global Alliance for TB Drug 
Development, Bill & Melinda Gates Foundation, UK Medical Research 
Council, and German Ministry of Science and Technology (grant 
number 01KA0901). We thank all patients who took part in this study. 
References
1 Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to 
achieve global tuberculosis control: progress and new 
developments. Lancet 2012; 379: 1902–13.
2 Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing 
the development of tuberculosis therapy. Nat Rev Drug Discov 2012; 
11: 171–72.
3 Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs 
are practical solutions for improving the treatment of tuberculosis. 
J Infect Dis 2012; 205 (suppl 2): S250–57.
4 Wallis RS, Perkins MD, Phillips M, et al. Predicting the outcome of 
therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 
2000; 161 (4 pt 1): 1076–80.
5 Yeager H LJ, Smith LR, LeMaistre CA. Quantitative studies of 
mycobacterial populations in sputum and saliva. Am Rev Respir Dis 
1967; 95: 998–1004.
6 Wright PW, Wallace RJ Jr, Wright NW, Brown BA, Griﬃ  th DE. 
Sensitivity of ﬂ uorochrome microscopy for detection of 
Mycobacterium tuberculosis versus nontuberculous mycobacteria. 
J Clin Microbiol 1998; 36: 1046–49.
7 Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. 
Randomized dose-ranging study of the 14-day early bactericidal 
activity of bedaquiline (TMC207) in patients with sputum 
microscopy smear-positive pulmonary tuberculosis. 
Antimicrob Agents Chemother 2013; 57: 2199–203.
8 Kayigire XA, Friedrich SO, Venter A, et al. Direct comparison of 
Xpert MTB/RIF assay with liquid and solid mycobacterial culture 
for quantiﬁ cation of early bactericidal activity. J Clin Microbiol 2013; 
51: 1894–98.
9 Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for 
multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 
366: 2151–60.
10 Mitchison DA. Assessment of new sterilizing drugs for treating 
pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 
1993; 147: 1062–63.
11 Pheiﬀ er C, Carroll NM, Beyers N, et al. Time to detection of 
Mycobacterium tuberculosis in BACTEC systems as a viable alternative 
to colony counting. Int J Tuberc Lung Dis 2008; 12: 792–98.
12 Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, 
Donald PR. Time to liquid culture positivity can substitute for 
colony counting on agar plates in early bactericidal activity studies 
of antituberculosis agents. Clin Microbiol Infect 2012; 18: 711–17.
13 Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to 
detection predicts month two culture conversion and relapse in 
non-HIV-infected patients. Int J Tuberc Lung Dis 2010; 14: 560–70.
14 Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for 
tuberculosis: progress, needs, and translation into practice. Lancet 
2010; 375: 1920–37.
15 Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. 
Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 
11: 343–54.
16 Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain 
reaction for assessing treatment response in patients with 
pulmonary tuberculosis. J Infect Dis 1994; 170: 713–16.
17 Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum 
Mycobacterium tuberculosis messenger RNA as a surrogate for 
response to chemotherapy. Am J Respir Crit Care Med 1999; 
160: 203–10.
18 Honeyborne I, McHugh TD, Phillips PP, et al. Molecular bacterial 
load assay, a culture-free biomarker for rapid and accurate 
quantiﬁ cation of sputum Mycobacterium tuberculosis bacillary load 
during treatment. J Clin Microbiol 2011; 49: 3905–11.
19 van Zyl-Smit RN, Binder A, Meldau R, et al. Comparison of 
quantitative techniques including Xpert MTB/RIF to evaluate 
mycobacterial burden. PLoS One 2011; 6: e28815.
20 Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium 
tuberculosis and rifampin resistance by use of on-demand, 
near-patient technology. J Clin Microbiol 2010; 48: 229–37.
21 Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/
RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV 
prevalence setting. Am J Respir Crit Care Med 2011; 184: 132–40.
22 Blakemore R, Nabeta P, Davidow AL, et al. A multi-site assessment 
of the quantitative capabilities of the Xpert(R) MTB/RIF assay. 
Am J Respir Crit Care Med 2011; 184: 1076–84.
23 Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular 
detection of tuberculosis and rifampin resistance. N Engl J Med 
2010; 363: 1005–15.
24 Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection 
of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert 
MTB/RIF assay—a clinical validation study. PLoS One 2011; 6: e20458.
25 Weyer K, Mirzayev F, Migliori G, et al. Rapid molecular TB 
diagnosis: evidence, policy-making and global implementation of 
Xpert(R)MTB/RIF. Eur Respir J 2012; published online Nov 22. 
DOI:10.1183/09031936.00157212.
Articles
470 www.thelancet.com/respiratory   Vol 1   August 2013
26 Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert 
MTB/RIF for diagnosis of TB and drug-resistant TB: a cost and 
aﬀ ordability analysis. Eur Respir J 2012; published online Dec 20. 
DOI:10.1183/09031936.00147912.
27 Kent PT, Kubica GP. Public health mycobacteriology: a guide for the 
level III laboratory. Atlanta, GA: US Department of Public Health 
and Human Services, 1985.
28 American Thoracic Society. Diagnostic standards and classiﬁ cation 
of tuberculosis in adults and children. Am J Respir Crit Care Med 
2000; 4: 1376–95.
29 Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the 
sterilising activities of oﬂ oxacin, gatiﬂ oxacin and moxiﬂ oxacin in 
pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128–38.
30 Blakemore R, Story E, Helb D, et al. Evaluation of the analytical 
performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 
48: 2495–501.
31 Garton NJ, Waddell SJ, Sherratt AL, et al. Cytological and transcript 
analyses reveal fat and lazy persister-like bacilli in tuberculous 
sputum. PLoS Med 2008; 5: e75.
32 Li L, Mahan CS, Palaci M, et al. Sputum Mycobacterium tuberculosis 
mRNA as a marker of bacteriologic clearance in response to 
antituberculosis therapy. J Clin Microbiol 2010; 48: 46–51.
33 Hellyer TJ, Fletcher TW, Bates JH, et al. Strand displacement 
ampliﬁ cation and the polymerase chain reaction for monitoring 
response to treatment in patients with pulmonary tuberculosis. 
J Infect Dis 1996; 173: 934–41.
34 Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM. Early 
tuberculosis treatment monitoring by Xpert(R) MTB/RIF. 
Eur Respir J 2012; 39: 1269–71.
